Biopharmaceutical Contract Manufacturing Market
2019 Analysis and Review of Biopharmaceutical Contract Manufacturing Market by Product Type - Monoclonal Antibodies, Recombinant Proteins, Vaccines, Insulin, Interferons, Growth Factors, and Others for 2019-2029
- 2020-01-23
- REP-GB-2982
- 40 Tables
- 105 Figures
- 221 pages
-
Press Release:
Biopharmaceutical Contract Manufacturing Market Projections
Biopharmaceutical Contract Manufacturing Market to Exhibit CAGR of Nearly 10%
Pharmaceutical incumbents tend to outsource biologics production due to limited accessibility to sources for formulating the final dose of medicines. Governments across the globe are heavily investing in the life science research sphere as part of their preventative healthcare strategy. Moreover, they are mapping out a certain portion of their biopharmaceutical spending for the domestic production of biologics. Exhibiting a dexterous CAGR of 9.8%, the biopharmaceutical contract manufacturing market is set to surpass the US$ 10 Bn mark in 2024. As per the FMI report, global revenue of the biopharmaceutical contract manufacturing market will surge 3X during 2019-2029.
Frequently Asked Questions about Biopharmaceutical Contract Manufacturing Market
How will the biopharmaceutical contract manufacturing market fare in the future?
Demand for biopharmaceutical contract manufacturing is poised to increase at a staggering CAGR of 10% over the forecast period. An increase in the focus on better and safer transportation and rise in the demand for pallets from food and transportation industries are expected to surge market growth.
Will the high capital investment of biologics manufacturing units affect the future trajectory of the market?
Yes, due to the involvement of high capital investment in the establishment of biologics manufacturing units, biopharmaceutical players are focusing on outsourcing bio-manufacturing. This has elevated the demand for CMOs in the biopharmaceutical contract manufacturing market space.
Which application area holds potential growth opportunities for players?
Demand from commercial biologics contract manufacturing holds the largest market share. The presence of a large number of FDA-approved biologics in the market is majorly driven due to the massive success of biopharmaceutical contract manufacturing.
What is the degree of competition in the biopharmaceutical contract manufacturing market?
Companies in the biopharmaceutical contract manufacturing market are making strategies of acquisition and collaborations to expand their business. Some of the companies are even involved in inorganic growth strategies, cross-selling, and encouraging longer-term relationships through increasingly comprehensive offerings.
Which region is at the forefront of the demand for biopharmaceutical contract manufacturing?
North America is poised to be the leading biopharmaceutical contract manufacturing market over the next decade. However, the reactor capacities of companies in the market are expected to move slightly from North America to Asia, due to rapid expansion in China, Singapore, and Korea, and government incentives and tax advantages, over the forecast period.Â
Mammalian-based Platform Accounts for 70% Share
Owing to their greater efficiency versus microbial-based cell culture, mammalian-based platforms such as Chinese hamster ovary (CHO) continue to remain a better choice for the production of biopharmaceuticals. With its adoption rate growing robustly, the revenue share of mammalian-based cell culture will follow an upward trajectory during the opportune time. By 2027, the application of mammalian-based platforms is likely to register over US$ 10 Bn in value. Moreover, demand growth of microbial-based platforms is expected to decline in the near future, due to high risks of cell contamination in micro-environment culture vessels.
North America in Vanguard, APEJ to Exhibit Market Attractiveness
Accounting for a collective share of around 60%, the biopharmaceutical contract manufacturing markets in North America and Western Europe are currently capturing significant portions of investments. While these developed regional markets are defining manufacturers’ bottom lines, accelerated adoption of biopharmaceutical contract manufacturing in Asia Pacific (Excluding Japan) is resulting in realignment of strategies. Cheaper manufacturing costs in this developing region are attracting various multinational biopharma companies for further R&D projects in biologic drugs.
* This data is only a representation. Actual data may vary and will be available in report.
-
2014
-
2018
-
2022
-
2029
Local Biologics Production to Set High Hopes
The current status of biologics development is influencing governments in developed and developing countries to significantly invest in advanced healthcare infrastructure. This is auguring well for the biopharmaceutical industry in these regions, which is further boosting the growth of the biopharmaceutical contract manufacturing market. The Government of Brazil, in a bid to improve overall biologics capacity, especially biosimilars and follow on biologics, has carved out a significant share of its healthcare expenditure for the local production of biologics. This increasing focus on enhancing domestic capacity would be an attention-grabbing factor for biopharmaceutical contract manufacturing organizations.
High preference for mammalian-based
Microbial-based to see promising demand growth
Surging demand for monoclonal antibodies
Recombinant proteins to gain rapid traction
Commercial application holds nearly 80% share
Adoption for clinical purposes to remain healthy
Oncology remains preferred therapeutic area
Preference for autoimmune diseases to rise rapidly
How Growth will Unfold
By capturing nearly half of the total market revenue, monoclonal antibodies (MaB) will continue to engage market players through 2029. The benefits of high specificity and clinical efficiency in treating chronic diseases, including cancer and other autoimmune diseases, are boosting the popularity of MaBs in the biopharmaceutical space. Although their exorbitant production costs are limiting their applicability in treating a broad array of infectious diseases, their use in laboratory and clinical settings is creating room for further novel and cost-efficient innovation such as plantibodies.
* This data is only a representation. Actual data may vary and will be available in report.
Click Here To Know How The Growth Will UnfoldCustom Market Research Services
FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.
Overview
Biopharmaceutical Contract Manufacturing Market Analysis 2019-2029
A recent market study published by Future Market Insights (FMI) on the biopharmaceutical contract manufacturing market offers global industry analysis for 2014-2018 and opportunity assessment for 2019-2029. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the biopharmaceutical contract manufacturing market, growth prospects of the market are obtained with maximum precision. The report features unique and salient factors that may make a huge impact on the development of the biopharmaceutical contract manufacturing market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the biopharmaceutical contract manufacturing market in the coming years. The report provides detailed information about the current and future growth prospects of the biopharmaceutical contract manufacturing market in the most comprehensive way for better understanding of readers.
Biopharmaceutical Contract Manufacturing Market Taxonomy
FMI’s study on the biopharmaceutical contract manufacturing market offers information divided into five important segments - platform, product type, application, therapeutic area, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Platform
- Mammalian-based
- Microbial-based
Product Type
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
- Insulin
- Interferons
- Growth Factors
- Others
Application
- Clinical
- Commercial
Therapeutic Area
- Autoimmune Disease
- Oncology
- Metabolic Disease
- Opthalmology
- Cardiovascular Disease
- Infectious Disease
- Neurology
- Respiratory Disorder
- Others
Region
- North America
- Latin America
- Western Europe
- Eastern Europe
- APEJ
- JAPAN
- Middle East and Africa
What's Included
The report commences with the executive summary of the biopharmaceutical contract manufacturing market report, which includes the summary of key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the biopharmaceutical contract manufacturing market.
Readers can find detailed taxonomy and the definition of the biopharmaceutical contract manufacturing market in this chapter, which helps readers understand the basic information about the biopharmaceutical contract manufacturing.
This chapter highlights the opeertunuties and macroeconomic factors of biopharmaceutical contract manufacturing market over the forecast period. Along with this section also explains the regulatory overview of the biopharmaceutical contract manufacturing market.
This section explains the global market value analysis and forecast for the biopharmaceutical contract manufacturing market during the forecast periods of 2019-2029. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2019), and an incremental $ opportunity for the forecast period (2019–2029).
This chapter explains how the biopharmaceutical contract manufacturing market will grow across various geographic regions such as North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, and the Middle East & Africa (MEA).
Based on platform type, the biopharmaceutical contract manufacturing market is segmented into mammalian-based and microbial-based. In this chapter, readers can find information about a detailed analysis of the market by different platform of biopharmaceutical contract manufacturing and their growth over the forecast period.
Based on Product type, the biopharmaceutical contract manufacturing market is segmented as monoclonal antibodies, recombinant proteins, vaccines, insulin, interferon, growth factors and others. This section helps the reader to gain knowledge about different products of biopharmaceutical contract manufacturing market.
Based on application, the biopharmaceutical contract manufacturing market is segmented as clinical and commercial. This section helps the reader to get information about the application of the biopharmaceutical contract manufacturing market over the forecast period.
Based on therapeutic area, the biopharmaceutical contract manufacturing market is segmented into Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder and Others. In this chapter, readers can find information on market attractive analysis based on different therapeutic of the market.
This chapter includes a detailed analysis of the growth of the North America biopharmaceutical contract manufacturing market along with the country-wise assessment including the U.S. and Canada. Readers can also find key takeaways of this region, and market growth based on platform type, product type, application, therapeutic area and country of biopharmaceutical contract manufacturing in the North American region.
This chapter includes the growth prospects of the biopharmaceutical contract manufacturing market in leading countries such as Brazil, Mexico, and the rest of Latin America. Readers can find thorough information about the growth parameters of the Latin America biopharmaceutical contract manufacturing market during the period 2019-2029.
Important growth prospects of the biopharmaceutical contract manufacturing market based on its platform type, product type, application, therapeutic area and country in several Western European countries such as the U.K., Germany, France, Italy, Spain, Russia, Nordic, BENELUX and Rest of Western Europe are included in this chapter.
This chapter highlights the market growth of biopharmaceutical contract manufacturing market in Eastern Europe by focusing on Russia, Poland and Rest of Eastern Europe. This section also helps the reader understand key factors responsible for growth of the biopharmaceutical contract manufacturing market in Eastern Europe.
China, India, ASEAN, Rest of APEJ are the leading countries in the APEJ region that are the prime subject of assessment to obtain growth prospects of the APEJ biopharmaceutical contract manufacturing market in this chapter. Readers can find thorough information about the growth parameters of the APEJ biopharmaceutical contract manufacturing market during the period 2019-2029.
Readers can find important factors that can make a huge impact on growth of the biopharmaceutical contract manufacturing market in Japan based on the market segmentation, during the forecast period. This chapter provides the highlights of the key factor impacting the growth of Japan biopharmaceutical contract manufacturing market over.
This chapter provides information on how the biopharmaceutical contract manufacturing market will grow in the major countries in MEA region, such as GCC Countries, South Africa, Northern Africa, and Rest of MEA during the period 2019-2029.
In this chapter, readers can find a comprehensive list of all the leading manufacturer in the biopharmaceutical contract manufacturing market along with detailed information about each company, including company overview, revenue shares, strategic overview, and recent company developments and SWOT analysis. Market players featured in the report include Lonza Group Ag, Baxter Biopharma solution, Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, Pfizer Centre Source Ltd (Pfizer Inc.), Novasep, Biomeva GmbH , Kbi Biopharma Inc., Rentschler Biotechnologie GmbH, and Ajinomoto Althea Inc. (Ajinomoto Co., Inc.).
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.
This chapter helps readers understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the biopharmaceutical contract manufacturing market.
How the research was conducted?
Primary Research
- C - Level Executives
- Marketing Directors
- Product Managers
- Business Development Officers
- Production Managers
- Procurement Heads
- Sales Executives
- Distributors
- Traders
- Raw Material Suppliers
- Industry Experts
- End Users
- Current Market Dynamics and Challenges
- Yesteryear Trends
- Market Characteristics
- Market Performance and Growth Quadrants
- Competition Structure and Market Structure
- Strategic Growth Initiatives
- Near-term and Long-term Market Growth Prospects
- Market Segment Splits and Authenticity
- Opinions on Market Projections and Validity of Assumptions
Secondary Research
- Industry Publications
- World Health Organizations (WHO)
- National Institute of Health (NIH)
- Factiva
- Company Press Releases
- Annual Reports and Investor Presentations
- Research Papers
- Government Websites and Publications
- Company Websites
- Morningstar
Primary Interview Splits
Biopharmaceutical Contract Manufacturing Market Reports - Table of Contents
18. Assumption and Acronyms Used
19. Research Methodology
To Learn More About our Comprehensive Perspective on Biopharmaceutical Contract Manufacturing Market,
Get in touch
Harish Tiwari
Global Head - Business Development
Pranay Mhaisekar
Client Partner - Global Business Development
Our Clients
CASE STUDIES
See how our work makes an impact.
At FMI, we design strategies that are adaptive, impactful, and implementable.